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BRIEF COMMUNICATIONS
SCREENING FOR SOLID ORGAN MALIGNANCIES PRIOR TO
HEART TRANSPLANTATION
VIVIANE M. CONRAADS,1,4 JOHAN DENOLLET,2 ANNE VORLAT,1 ADRIAAN C. MOULIJN,3 AND
CHRISTIAAN J. VRINTS1
Department of Cardiology and Department of Cardiac Surgery, University Hospital Antwerp, Belgium; and Department of
Clinical Health Psychology, Tilburg University, The Netherlands
Background. Prognosis of solid organ cancer in im-
munosuppressed hosts is generally dismal. Therefore,
every effort to identify patients with asymptomatic
carcinomas before transplantation should be
encouraged.
Methods. Sixty-seven patients referred for heart
transplantation were examined adhering to the
scheme proposed at the 24th Bethesda Conference. To
increase the sensitivity of this work-up, the following
items were added: tumor marker assays (prostate-spe-
cific antigen in males, carcino embryogenic antigen),
abdominal ultrasound, CT scan of the abdomen and
the thorax, mammography/echography of the breasts,
PAP smear, colonoscopy if carcino embryogenic anti-
gen abnormal or occult blood in stool, prostate echog-
raphy if prostate-specific antigen abnormal or pros-
tate hypertrophy.
Results. Carcinoma was detected in 10 of the 67 pa-
tients; for 8 patients of this cancer group, transplan-
tation was denied. Importantly, 9 of the 10 malignan-
cies were detected by means of the diagnostic items
that were added to the standard screening protocol.
There were no significant differences between the
cancer and the non-cancer group regarding mean age,
sex, etiology of heart failure, and smoking history.
Stratifying patients in younger (i.e., <54 years) and
older (i.e., >55 years) age groups showed a signifi-
cantly greater proportion of older patients in the can-
cer group (8/10580%) compared to the non-cancer
group (25/57544%), P50.04. After a mean follow-up of
34 months, 5 of the 36 transplanted patients developed
a malignancy (4 skin carcinomas, 1 non-Hodgkin lym-
phoma). There have been no malignancy-related
deaths until now.
Conclusion. The importance of a thorough screening
program in the triage of candidates with preexisting
malignancies, especially in an older patient popula-
tion, is illustrated in this report.
INTRODUCTION
Heart transplantation has become an accepted and highly
successful therapy for end-stage cardiac failure. The lack of
suitable donor hearts is emphasised by an unrelentingly
increasing pool of heart failure patients and hence an unac-
ceptable mortality rate on waiting lists. It is therefore man-
datory for transplant programs to insist on a severe and
thorough screening of possible recipients to ensure optimal
morbidity and mortality after transplantation.
Long-term survival after heart transplantation is deter-
mined by allograft vasculopathy and the emergence of ma-
lignant diseases. Although difficult to prove, it is likely that
at least part of these carcinomas are present before trans-
plantation, and would perhaps be detectable with appropri-
ate and sensitive tools. We therefore decided to broaden the
screening program imposed on transplant candidates in our
centre by adding several imaging techniques and tumor
marker assays to the proposed scheme at the 24th Bethesda
conference (1). The initial findings of our study suggest a
common pathway in the etiology of both severe heart failure
and cancer. A comparable relation has been put forward
between the development of cancer and ischemic heart dis-
ease (2).
Between June 1, 1994 and July 31, 2000, 67 patients (pts)
referred for heart transplantation underwent an extensive
screening program. We used the scheme published in the
Task Force by the American College of Cardiology (1) in 1993
as a basis and added several items as shown in Table 1. Mean
age was 53.1 years and 43 patients (64%) were male. Etiology
of heart failure was ischemic in 39 patients (58%), idiopathic
in 22 patients (33%), and of other origin in 6 patients (9%). Of
the total group, 36 patients received a cardiac allograft. Nine-
teen were not accepted for transplantation because they were
considered too well (5 pts) or presented with one or more
contraindications (14 pts). Five patients died on the waiting
list and 6 patients were removed from the list because of
significant improvement.
In 10 patients, screening led to the diagnosis of a malig-
nant lesion (cancer group) (Table 2). Nine of these patients
presented without any symptoms or clinical evidence of these
cancers. Moreover, in each of them, suspicion was raised
after one or more of the extra investigations were found to be
abnormal. Patients 1, 4, and 7 had a completely normal
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clinical breast examination. The vaginal in situ carcinoma of
patient 2 was not palpable. In patient 3, elevated CEA (17
ng/ml, normal value ,6 ng/ml) led to diagnostic colonoscopy.
The lung carcinoma detected by CT scan of the thorax in
patient 6 was not visible on the routine chest x-ray. Rectal
examination in patient 8 revealed an enlarged prostate with-
out suspicious irregularities. The hypernephroma and blad-
dercarcinoma in patients 9 and 10 were first visualised by CT
scan of the abdomen. In patient 5, repetitive bouts of low-
grade fever eventually led to a diagnostic bone marrow bi-
opsy. The age at the time of diagnosis, etiology of heart
failure, sex, and type of malignancy and diagnostic tests are
depicted in Table 2. Of this group, eight patients were not
accepted for transplantation. Two patients (nos. 2 and 3)
were transplanted after a curative resection of an in situ
carcinoma was carried out.
At the time of referral, there were no significant differ-
ences in sex, heart failure etiology, or known risk factors for
malignancy between the non-cancer and the cancer group.
Although patients in the cancer group tended to be older, the
difference in mean age was only marginally significant (mean
age cancer group 59.969.4 years, versus non-cancer group
52.3612.7 years, P50.08, 2-tailed t test). Stratifying patients
in younger (i.e., #54 years) and older (i.e., $55 years) age
groups showed a significantly greater proportion of older
patients in the cancer group (8/10580%) compared to the
non-cancer group (25/57544%), P50.04.
Of the transplanted group (mean follow-up of 34 months),
four patients underwent resection of a skin tumor (two basal
cell carcinomas, two squamous cell carcinomas). A 60-year-
old man developed EBV related non-Hodgkin lymphoma in
combination with adenocarcinoma. He is doing well 2 years
after a combined therapy (surgical resection and chemother-
apy), without disease recurrence. The two patients who re-
ceived a cardiac allograft despite the finding of a vaginal in
situ carcinoma and a neoplastic polyp respectively, are doing
well, now more than 4 years after transplantation.
DISCUSSION
Evidence suggests that there is a disproportionately high
incidence of neoplasia after allograft transplantation when
compared to a matched general population (3). There is in-
deed ample proof that posttransplant lymphoproliferative
diseases (PTLD) and skin cancers are elicited by the use of
immunosuppressive drugs. Evidence for a significant in-
crease in the incidence of those neoplasms that are observed
frequently in the general population is conflicting. Recently,
information gathered from the Cardiac Transplant Research
Database (CTRD) (4) revealed the clear distribution of time
specific risks for mortality after transplantation. Malignancy
(both PTLD and nonlymphoma) was the cause of death in
8.4% of 5.888 heart transplant recipients with a mean fol-
low-up of 39 months. The risk of death from cancer was
relatively constant during the first 4 years after transplan-
tation with a slight raise at 5 to 7 years and a marked
increase after 7 years (annual risk of death of 7.19 at year 8).
Olivari et al. reported an incidence of malignancy of 10%
(excluding skin cancer) in their analysis of a group of 228
patients transplanted between 1985 and 1998 (5). Solid or-
gan tumors (SOT) were diagnosed in 16 patients, a median of
48 months after heart transplantation. There was a signifi-
cant relation with OKT3 treatment. Most of the tumors were
squamous cell carcinomas of the lung (five patients). In this
series, as well as in others, PTLD occured earlier then SOT
(median follow- up of 10 months versus 48 months for SOT),
but prognosis was better (57% after 44 months for PTLD,
37% survival after 25 months for SOT).
Although difficult to prove, it is likely that at least part of
the malignancies discovered after transplantation are al-
ready present before the administration of immunosuppres-
sant therapy and from then on show an accelerated growth
rate. Hence, diagnosis in an early stage is challenging and
consequently, a cure remains exceptional (6, 7). It seems
therefore appropriate to focus on the detection of previously
unknown malignancies during the screening period of poten-
tial transplant recipients.






CT scan of the abdomen
CT scan of the thorax
Mammography
Echography of the breast
PAP smear (F)
Colonoscopy in case of 1 CEA or occult blood in stool
Transrectal prostatic echography if 1 PSA or prostatic
hypertrophy
a Abbreviations: PSA, prostate specific antigen; CEA, carcino em-
bryogenic antigen; F, females; M, males; PH, prostate hypertrophy.
TABLE 2. Clinical and demographic features of patients with malignancy before transplantation
Pta Sex Age (yr) Malignancy Tx Etiology of HF Diagnostic test
1 F 64 Breast ca Denied Idiop Mammo/echo
2 F 59 Vaginal ca Transplanted Idiop PAP
3 M 55 Colon ca Transplanted Isch CEA
4 F 40 Breast ca Denied Isch Mammo/echo
5 M 58 Lymphoma Denied Isch Clinical
6 F 51 Lung adeno ca Denied Other CT-Thorax
7 F 66 Breast ca Denied Idiop Mammo/echo
8 M 72 Prostate ca Denied Isch PSA
9 F 67 Hypernephroma Denied Isch CT-abdomen
10 M 66 Bladder carcinoma Denied Idiop CT-abdomen
a Abbreviations: Pt, patient; Tx, transplantation; HF, heart failure; F, female; M, male; ca, carcinoma; isch, ischemic; idiop, idiopathic;
CEA, carcino embryogenic antigen; PSA, prostate specific antigen.
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To exclude patients with clinically silent but relevant ma-
lignancies, we decided to broaden the classically adhered
screening scheme by adding several imaging techniques and
tumor marker assays. The finding that of the 67 patients
referred for transplantation, 10 presented to us with a ma-
lignant disease, was striking and difficult to explain. In the
cancer group, 80% of the patients were 55 years or older,
whereas in the non-cancer group this percentage was much
lower (44%). However, the incidence of malignancy in both
groups is still much higher than the age-adjusted figures for
the regional Flemisch population (cancer incidence including
nonmelanoma skin tumors: 388/100,000 for women,
278/100,000 for men aged 50–54 years, 444/100,000 for
women and 500/100,000 for men aged 54–60 years).
With respect to risk factors for the development of solid
organ malignancies after heart transplantation, research has
mainly focused on smoking habits. Several series have shown
that the current or past exposure to tobacco was undoubtedly
related to the development of lung cancer after transplanta-
tion with an outcome that was invariably infaust (6, 7). There
was no difference in heart failure etiology between the cancer
and the non-cancer group and thus risk factors such as to-
bacco use, which could be a common denominator for both
ischemic cardiomyopathy and for instance lung cancer, were
probably not at play. Particular risk factors for specific ma-
lignancies (e.g., familiar occurrence of breast or colon cancer)
were not present.
Although the long-term benefit and the effect on the occur-
rence of malignancies of our extensive screening program
should be awaited, it seems without doubt that the patients
in the cancer-group would have developed clinically overt
disease after transplantation. Therefore, in view of our find-
ings, the elaboration of a more exhaustive schedule of inves-
tigations to safely select transplant candidates seems advis-
able, especially in older patients.
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LATE ONSET OF SEVERE GRAFT-VERSUS-HOST DISEASE IN A
PEDIATRIC LIVER TRANSPLANT RECIPIENT
STEPHEN P. DUNN,1,2,5 LESLIE J. KRUEGER,1,2 LAVAY BUTANI,3 AND HOPE PUNNETT4
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We report the management of a patient with the late
onset of chronic graft-versus-host disease (GVHD) af-
ter orthotopic liver transplantation. GVHD is a rare
complication of solid organ transplants that usually
presents early after transplantation and is fatal in the
majority of cases. Our patient differs from the typical
patient with GVHD in that the onset of her disease was
very late. Although most treatment to date consisted
of an increase in immunosuppressive therapy, our pa-
tient showed an excellent response to a reduction.
This resulted in the abatement of the symptoms of
GVHD and the preservation of her allograft function.
Cellular graft-versus-host disease (GVHD) is a frequent
complication after bone marrow transplantation (1, 2). In
addition to the cellular form, another type of GVHD, mani-
festing as an antibody-mediated hemolytic anemia, is also
reported among recipients of liver, intestine, and kidney
transplants (3–5). GVHD is acknowledged as a distinctly
uncommon entity in solid organ transplant recipients (6–8);
however, both humoral and cellular GVHD have been re-
ported in liver transplant patients. Although it is rare in liver
transplant recipients, when it occurs, it has uniformly been
noted early in the posttransplant period. Additionally, in
spite of the institution of aggressive immunosuppressive
therapy, GVHD is often lethal (8, 9).
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